Capenon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Capenon

Property Description
Active Ingredients Amlodipine, Olmesartan Medoxomil
Form Film-coated tablet
Pharmacological Class Antihypertensive Agents (CCB and ARB)
Common Use Management of High Blood Pressure (Hypertension)
Origin Synthetic Chemical Compounds

Capenon is a prescription medication designed to address high blood pressure (hypertension) using a fixed-dose combination of two distinct, established active ingredients within a single pharmaceutical entity. This approach classifies Capenon as a synthetic product intended for oral therapy. This formulation is clinically recognized for providing a comprehensive approach to lowering blood pressure in adults whose condition is not adequately controlled by either monotherapy alone.

What Type of Antihypertensive Medicine is Capenon?

Capenon belongs to the broader class of antihypertensive agents, which are medicines specifically used to reduce elevated blood pressure. It is classified as a dual-action therapy, combining components from two different pharmacological groups: Amlodipine, a calcium channel blocker (CCB), and Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB). The specific pairing of a CCB and an ARB within Capenon offers a strategic therapeutic differentiation, leveraging two complementary pathways compared to formulations that combine agents from similar classes.

Capenon's Dual Composition and General Purpose

The product is supplied as a film-coated tablet and contains the two active ingredients, Amlodipine and Olmesartan Medoxomil, combined with various excipients. The general purpose of this combination is to achieve a synergistic effect, which provides a more robust and effective reduction in blood pressure. This effect is rooted in the strategic principle of lowering vascular resistance by simultaneously causing the relaxation of blood vessel walls (Amlodipine) and inhibiting a powerful hormonal signal that causes vessel narrowing (Olmesartan Medoxomil). This dual mechanism is the key to maintaining a healthier, lower blood pressure level, often employed when a patient requires simultaneous control of both hormonal and mechanical factors contributing to their hypertension.

What side effects are possible with Capenon?

Possible side effects and safety information

The safety profile for Capenon, a combination of Amlodipine and Olmesartan Medoxomil, is derived from regulatory classifications that group observed adverse reactions by frequency and physiological system. This structured documentation provides the official overview of the medicine’s risk characteristics, focusing exclusively on documented effects.


Frequency-Classified Adverse Reactions

The most frequently documented event is Oedema (swelling), typically peripheral, which is classified as Very Common and is primarily associated with the Amlodipine component. Reactions classified as Common include dizziness, headache, and fatigue. Less frequent events classified as Uncommon include hypotension and syncope.


System-Organ Classes and Serious Reactions

The adverse reactions are categorized across several System-Organ Classes, including the Nervous System (headache, dizziness), Vascular Disorders (hypotension, flushing), and Gastrointestinal Disorders (nausea, abdominal pain). Serious adverse reactions explicitly documented in official labeling include Angioedema (severe swelling) and Acute Renal Failure. The Olmesartan component is associated with a specific, rare reaction known as Sprue-like enteropathy, characterized by chronic, severe diarrhea and weight loss, which may occur after prolonged use.


Population-Specific Safety Constraints

The regulatory profile outlines specific constraints for certain populations. The product is contraindicated during the second and third trimesters of pregnancy due to the Olmesartan component. Furthermore, use is not recommended in patients with severe hepatic impairment due to increased systemic exposure. Official documents also note that effects such as dizziness and headache are explicitly documented as being more common at the beginning of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Profile

The following information details the formally documented descriptions of overdose for Capenon (Amlodipine/Olmesartan Medoxomil) and the actions mandated by regulatory authorities.


Documented Overdose Manifestations

Official labeling states that overdose may result in profound and prolonged systemic hypotension, which is the most significant clinical sign due to excessive peripheral vasodilation from the amlodipine component. Other documented effects include tachycardia (reflex heart rate increase) and, in some cases, bradycardia. The most severe life-threatening consequence cited is the potential for progression to shock or acute myocardial infarction secondary to sustained, profound hypotension.


Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. Regulatory documents mandate active support of the cardiovascular system, including close monitoring of heart and lung function in a hospital setting. Management involves providing symptomatic and supportive treatment. Procedural steps documented include placing the patient in the supine position and administering intravenous fluid resuscitation; vasopressor agents may be needed if hypotension is unresponsive to fluids. The prescribing information notes that no specific antidote is known for either active ingredient. Monitoring of renal function and serum electrolytes is also required due to the components' known effects. Individuals with hepatic impairment may experience a more prolonged severity of symptoms.

Therapeutic Uses of Capenon

What Capenon Treats: Main Uses and Benefits

Capenon is commonly used in clinical settings that involve chronic management of essential hypertension (high blood pressure) in adults. It is typically prescribed when a patient’s blood pressure is generally not adequately controlled by therapy with a single blood pressure-lowering medication. Its uses include addressing persistent, elevated blood pressure and contributing to the ease of risk associated with chronic cardiovascular strain. The combination of active ingredients is commonly used to help achieve blood pressure goals when single-agent therapy is not sufficient.


Understanding the Therapeutic Benefit

This medication is applied in addressing conditions characterized by persistent, elevated blood pressure and is relevant in contexts marked by increased discomfort or tension. The medication is relevant for easing symptoms related to systemic imbalance and noticeable physiological strain.

Indications: Capenon is commonly used for essential hypertension in situations where a combination approach is appropriate for managing blood pressure.

“This therapeutic approach may assist with maintaining functional stability during periods of chronic physiological stress.”

The benefit of managing blood pressure is the supportive role in easing the risk of complications associated with chronic hypertension, which may assist with maintaining functional stability.


Quick Fact Block

Quick Fact: Support for Blood Pressure Management

This medication supports the management of systemic imbalance, which may contribute to easing the overall symptom load associated with chronic high blood pressure.

Regulatory References

  1. Public Assessment Report from the Dutch Medicines Evaluation Board

Eligibility and Restrictions for Use

Who can and cannot use Capenon? — Official Regulatory Information

Capenon (amlodipine/olmesartan medoxomil) is authorized for use in adult patients with high blood pressure (essential hypertension). Eligibility for use is strictly defined by regulatory documents based on age, concurrent medical conditions, and physiological status.

Eligibility Scope Official Regulatory Documentation Statement
Populations for whom use is allowed Adult patients (18 years and above) whose blood pressure is not adequately controlled by single-agent therapy.
Populations for whom use is contraindicated Patients who become pregnant (immediate discontinuation is required). Patients with known hypersensitivity to the components or dihydropyridine derivatives. Patients with diabetes receiving aliskiren. Patients with severe hypotension or cardiogenic shock.
Age-related eligibility rules Use is not recommended in children and adolescents below 18 years due to insufficient data. Initial therapy is not recommended for patients ge 75 years old.
Condition-specific eligibility rules Use is not recommended in severe hepatic impairment or severe renal impairment (creatinine clearance le 20 mL/min).
Pregnancy and lactation eligibility Pregnancy is a contraindication due to the risk of fetal injury and death. Use is not recommended for women who are breastfeeding.

Eligibility is also restricted for patients with severe heart valve conditions (e.g., aortic stenosis) or who are volume-depleted, requiring close medical supervision.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe a structured profile of interactions for Capenon, which contains Amlodipine and Olmesartan Medoxomil.

Classification Interacting Substance/Class Official Regulatory Statement
Contraindicated Aliskiren Prohibited in patients with diabetes or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m^2) due to increased risk of hyperkalemia and renal failure.
Exposure Impact CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin) Significantly increase Amlodipine plasma concentration (exposure).
Exposure Impact Simvastatin Amlodipine causes a significant increase in Simvastatin exposure; the maximum daily dose for Simvastatin should be restricted.
Pharmacodynamic Agents Increasing Potassium (e.g., potassium-sparing diuretics) Increase the risk of hyperkalemia (elevated serum potassium levels).
Pharmacodynamic NSAIDs (including COX-2 inhibitors) Increase the risk of renal function deterioration and may reduce the blood pressure-lowering effect.
Timing Rule Colesevelam Hydrochloride The Olmesartan component must be administered at least 4 hours prior to Colesevelam to prevent a documented reduction in Olmesartan bioavailability.
Special Caution Lithium Not recommended due to reports of increased serum Lithium concentrations and risk of toxicity.

Co-administration with Grapefruit or Grapefruit Juice is officially discouraged as it may increase Amlodipine exposure. Furthermore, the combination product is not recommended for use in patients with severe hepatic impairment due to the documented potential for increased drug exposure for both active components.

Mechanism of Action

Capenon as a Glutathione Peroxidase Mimetic

Capenon’s primary action involves acting as an enzyme mimetic for the naturally occurring Glutathione Peroxidase (GPx), utilizing intracellular glutathione (GSH) as a co-substrate. This interaction enables Capenon to rapidly neutralize reactive oxygen species (ROS), such as hydrogen peroxide (H2O2). The mechanistic cascade prevents damaging molecular events, including lipid peroxidation, which contributes to an overall cytoprotective effect.

Modulation of Redox-Sensitive Signaling

By controlling the concentration of ROS and shifting the cellular redox state (GSH/GSSG ratio), Capenon indirectly modulates key redox-sensitive signaling pathways and transcription factors (e.g., NF-kB). This signaling alteration influences gene expression patterns, which, in turn, modulates the signaling activity of inflammatory pathways.

Functional Modification of Metallo-Proteins

Capenon is also classified as a modulator of specific metallo-proteins and other enzymes containing reactive thiol groups at their active sites. This involves temporary chemical modification that can inhibit protein function. This modification acts to regulate the overall function of these proteins, providing a distinct mechanism of functional adjustment in systems dependent on these sensitive chemical residues.

Dosage and Administration Information

How to Use Capenon: Administration Guidelines

Capenon (Amlodipine/Olmesartan Medoxomil) is a fixed-dose combination product administered orally as a film-coated tablet for the long-term management of hypertension. The usage principles are defined to ensure consistent daily dosing.

Standard Labeled Dosing and Administration

The medication is taken once daily. The tablet may be taken with or without food but should be swallowed whole with a sufficient amount of fluid and should not be chewed. It is important to maintain consistency by taking the dose at approximately the same time each day.

Dosing Parameter Instruction (Adults)
Starting Dose Typically 5/20 mg once daily.
Maximum Dose 10/40 mg once daily.
Dose Titration Dosage can be increased, if needed, after waiting for approximately 1 to 2 weeks following the previous dose adjustment.

Administration for Specific Populations

Standard administration guidelines include limitations for certain patient groups. The fixed-dose combination is not established for use in pediatric patients. In older adults (e.g., 75 years and older), initiating therapy with the fixed combination is generally not recommended; instead, individual components should be initiated separately.

For patients with severe hepatic impairment or severe renal impairment (CrCl < 20 mL/min), the use of Capenon is not recommended. In cases of mild to moderate hepatic impairment, dose selection requires caution.

Missed Dose Protocol

If a dose of Capenon is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time the following day. Doses should not be doubled.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Capenon

Evidence for Use in Essential Hypertension

The clinical evaluation of Capenon, the fixed-dose combination of Amlodipine and Olmesartan Medoxomil, focused on the chronic management of high blood pressure (essential hypertension). Research primarily involves short-term, randomized, controlled trials (RCTs), where the combination was evaluated against a placebo and against the individual medications taken alone. These trials examined patients whose blood pressure levels were not adequately controlled by a single medication.

Evaluation of Blood Pressure Outcomes in Clinical Trials

Studies monitored specific, measurable outcomes related to physiological strain, primarily the change from baseline in the Seated Systolic and Diastolic Blood Pressure (SeSBP/SeDBP). Research also describes the use of 24-hour Ambulatory Blood Pressure Monitoring (ABPM) to observe whether blood pressure changes were sustained over the full dosing interval. Furthermore, studies monitored the proportion of patients whose measurements fell below specific, predefined target levels by the end of the trial period. Patient subgroups with common concurrent health conditions, such as Type 2 Diabetes, were also evaluated.

Key Research Gaps and Remaining Uncertainties

Core research supporting the combination typically involved treatment periods of only 8 to 12 weeks, meaning there is limited information for long-term outcomes regarding the durability of blood pressure management. The clinical trials focused on measuring changes in blood pressure levels, a surrogate endpoint, and not on the long-term impact on major cardiovascular events (e.g., stroke or heart attack). Dedicated, long-term trials to directly monitor this combination’s influence on hard health events are limited. Data for certain groups, such as the very elderly or those with severe kidney issues, remain insufficient.

Key Studies & References

  1. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
  2. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands: SEVIKAR film-coated tablets (Olmesartan/Amlodipine)
  3. The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension (SEVITENSION Study)

Frequently Asked Questions (FAQ)

Common questions about Capenon (FAQ)

Q: How quickly should I expect to feel any effects from Capenon?

Official product information indicates that the maximum blood pressure lowering effects from a dose adjustment of Capenon are typically reached within approximately 1 to 2 weeks. Information in the product label notes that blood pressure management with Capenon is typically focused on long-term control.


Q: What happens if I accidentally miss a dose of Capenon?

Regulatory guidance instructs that if a dose of Capenon is missed, the dose should be skipped entirely. Official instructions state that the next dose should be taken at the regularly scheduled time the following day. Doses should not be doubled to make up for a missed one.


Q: Is it normal to feel a bit nauseous when first starting Capenon?

Official safety data lists nausea as a reported side effect. While the documentation notes that nervous system effects like dizziness and headache are explicitly more common at the beginning of treatment, any persistent nausea is an event that may warrant discussion with a healthcare provider.


Q: What should I do if my side effects don't go away after a few weeks on Capenon?

Official regulatory text notes that some side effects may be more common at the beginning of treatment. Any persistent adverse reaction is often an event that should be reported to a healthcare provider for evaluation. Discontinuation or modification of treatment is determined by a medical professional.


Q: Does Capenon affect the results of common lab tests?

Regulatory documents explicitly warn of an increased risk of elevated serum potassium levels (hyperkalemia) and potential changes in renal (kidney) function. The potential for changes in renal function or serum potassium levels means that laboratory monitoring of these factors may be warranted.


Q: How does my medical condition relate to the way Capenon works?

Capenon is officially indicated for treating high blood pressure (hypertension). The medication works by combining two mechanisms: the amlodipine component helps relax blood vessels, and the olmesartan component blocks a hormone that normally causes vessel narrowing, resulting in an overall blood pressure reduction.


Q: What are common patient misunderstandings about how Capenon works?

The official documentation classifies Capenon as a dual-action medicine, combining a Calcium Channel Blocker (CCB) and an Angiotensin II Receptor Blocker (ARB). The strategic principle is to use two different types of blood pressure lowering agents to achieve a more effective reduction in blood pressure than either agent alone.


Q: Does Capenon have any known interactions with herbal supplements?

The official product labeling does not typically contain information regarding common herbal supplements. However, official information does warn against the use of potassium-containing supplements and salt substitutes because the olmesartan component can affect potassium levels.


Q: What kind of monitoring might be needed while taking Capenon?

Due to the potential effects of the active components, official safety guidelines suggest that monitoring may include checks of blood pressure, renal (kidney) function, and serum potassium levels. This is typically done through periodic blood work, especially when starting treatment or adjusting the dosage.


Q: Is Capenon used for other things besides its main purpose?

No. The official indication, as defined by regulatory agencies, is the treatment of hypertension (high blood pressure), alone or in combination with other agents. Regulatory documents do not define any other uses for this product.


Q: What is the longest someone typically uses Capenon for?

Capenon is indicated for the treatment of hypertension, which is generally a chronic medical condition requiring continuous, long-term management. While the core studies supporting approval were short-term, the medicine is intended for sustained management.


Q: Do I need to change my diet while taking Capenon?

Official labeling advises against consuming Grapefruit or Grapefruit Juice because it may increase the amount of amlodipine in the blood. Caution is also noted regarding the use of salt substitutes or other potassium-rich products due to the olmesartan component.


Q: Is Capenon a type of antibiotic?

No. Capenon is classified as a combination of two different types of antihypertensive agents: a Calcium Channel Blocker (CCB) and an Angiotensin II Receptor Blocker (ARB). It is used exclusively to lower blood pressure.


Q: Does Capenon interact with alcohol, and what kind of reaction could happen?

Official safety information for blood pressure-lowering medications often notes the need for caution regarding alcohol. Consuming alcohol may cause an additive blood pressure lowering effect, which could lead to common side effects such as dizziness or lightheadedness.


Q: Why does Capenon cause drowsiness in some people?

Official documentation lists dizziness and fatigue (tiredness) as common adverse reactions. These effects can sometimes be related to the medicine's overall action of lowering blood pressure, which may result in feelings of lightheadedness or low energy.


Q: Are the side effects of Capenon permanent?

Reported adverse reactions are typically considered reversible when treatment is discontinued. However, official safety documentation notes that rare but serious reactions, such as Sprue-like enteropathy (linked to the olmesartan component) or Acute Renal Failure, are documented.


Q: What is the difference between Capenon and a supplement I might buy at a store?

Capenon is a prescription-only pharmaceutical product containing chemically defined active ingredients. It is subject to rigorous government regulatory approval for the treatment of a specific medical condition (hypertension), unlike dietary supplements.


Q: Why do some people need to stop taking Capenon suddenly?

Regulatory sources define specific situations where immediate discontinuation is required. These include the detection of pregnancy, or the occurrence of certain severe adverse reactions such as angioedema (severe swelling) or signs of severe renal failure or hypotension.


Q: Does Capenon make you gain or lose weight?

Official safety data lists Oedema (swelling or fluid retention), which is a very common side effect. Separately, the olmesartan component is associated with a rare reaction called Sprue-like enteropathy, which may involve symptoms of chronic diarrhea and weight loss.


Q: Are there any specific vitamins or minerals that interact with Capenon?

Official labeling specifically warns against using potassium supplements or salt substitutes. Because the medicine contains olmesartan, using these products can increase the risk of developing hyperkalemia (dangerously high potassium levels) in the blood.


Q: Is Capenon a controlled substance?

No. Official government classification lists Capenon (amlodipine/olmesartan medoxomil) as a non-controlled prescription medicine.


Q: If I have a mild reaction, should I stop Capenon right away?

Regulatory guidelines emphasize that treatment for chronic conditions like high blood pressure should be continuous. Decisions to stop or change treatment, even due to a mild reaction, are appropriate to be made in consultation with a healthcare provider.


Q: Is it possible to become dependent on Capenon?

Official regulatory information, which includes the drug abuse and dependence section, does not list the active components of Capenon as having the potential for drug abuse or dependence.


Q: What are the long-term effects of taking Capenon for many years?

Capenon is prescribed for the long-term management of high blood pressure to help reduce the risk of future cardiovascular problems. However, the core clinical trials supporting the combination were typically short-term (8–12 weeks), meaning direct evidence on outcomes over many years is limited.


Q: Is there a generic version of Capenon available?

Yes. The active ingredients in Capenon, amlodipine and olmesartan medoxomil, are available in a generic fixed-dose combination from multiple manufacturers. This generic fixed-dose combination is officially approved and available.


Q: Are there any foods I absolutely must avoid while on Capenon?

Official regulatory documents specifically advise patients to avoid consuming Grapefruit or Grapefruit Juice while taking this medication. This is due to a documented interaction with the amlodipine component.


Q: Does Capenon cause problems with sleep?

While the specific adverse reaction of insomnia is not listed as common in the official safety profile, other nervous system effects, such as dizziness and fatigue, are frequently reported by patients.


Q: Is the effectiveness of Capenon consistent across all age groups?

Clinical trials provided evidence of blood pressure lowering across various age groups. However, initial therapy with the fixed combination is not recommended for adults 75 years of age and older due to potential differences in how the body processes the medication components in this population.


Q: Can Capenon affect my energy levels during the day?

Yes, official safety documents list fatigue (a feeling of tiredness or low energy) as a common adverse reaction reported by patients taking Capenon.


Q: What is the typical time frame for a follow-up appointment after starting Capenon?

Official dosing guidelines recommend waiting approximately 1 to 2 weeks after any dose adjustment before making another change. This timeline is often used as a benchmark for a follow-up assessment to check the effectiveness of the current dose on blood pressure.


Q: Is Capenon a drug that is only used for chronic conditions?

Capenon is officially indicated for the treatment of hypertension (high blood pressure). Hypertension is generally considered a chronic medical condition that requires continuous, long-term management.


Q: Can I take Capenon if I have a history of allergic reactions to medicines?

Capenon is explicitly contraindicated (should not be used) if you have a known hypersensitivity or severe allergic reaction to its active components or to any other drug derived from the dihydropyridine class.


Q: How soon after stopping Capenon does it completely leave the body?

The time it takes for Capenon to be eliminated is determined by its two components. The amlodipine component has a documented half-life of approximately 30 to 50 hours, and the olmesartan component has a half-life of approximately 13 hours.


Q: Is there a maximum time Capenon can be used before a break is needed?

Regulatory documents indicate that Capenon is a treatment for chronic hypertension, which requires continuous management. There is no regulatory requirement in the official labeling that mandates taking a break from the medication.

How should Capenon be stored and disposed of?

Capenon Storage and Disposal Requirements

Capenon must be stored strictly according to the conditions defined in the official regulatory labeling.

Storage Conditions

Requirement Official Instruction
Temperature Store at 25 C (77 F), with controlled excursions permitted up to 30 C.
Protection Protect from light and moisture; keep tablets in the original package and the container tightly closed.
Safety The medicine must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of unused or expired Capenon must align with regulatory guidance. It is required to dispose of the product according to local requirements and consult a pharmacist for guidance. Medicines should not be disposed of via wastewater or household waste (trash) to prevent environmental contamination, as per official documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Capenon found in:

A-Z Index: